Trial Profile
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine; Cisplatin; Fluorouracil
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors ASLAN Pharmaceuticals
- 19 Jan 2019 Pooled analysis results evaluating efficacy and safety of varlitinib from studies NCT02648425, NCT02435927 and NCT02992340 were presented at the 2019 Gastrointestinal Cancers Symposium.
- 08 Jan 2018 Status changed from recruiting to completed.
- 06 Jun 2017 Initial results assessing the (n=27) safety and efficacy of varlitinib in combination with cisplatin and 5-fluorouracil or cisplatin and capecitabine in patients with metastatic solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.